Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of AMG 386 and Temsirolimus in Advanced Solid Tumors With an Expansion Cohort in Uterine Cancer, Renal Cell Carcinoma and Carcinoid Tumor

NCT01548482 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01548482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01548482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of AMG 386 and Temsirolimus in Advanced Solid Tumors With an Expansion Cohort in Uterine Cancer, Renal Cell Carcinoma and Carcinoid Tumor
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2012
Completion date
January 31, 2014
Enrollment
21 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

adult solid neoplasm, lung carcinoid tumor, recurrent digestive system neuroendocrine tumor g1, recurrent renal cell carcinoma, recurrent uterine corpus sarcoma, stage iii renal cell cancer, stage iiib uterine sarcoma, stage iiic uterine sarcoma, stage iv renal cell cancer, stage iva uterine sarcoma, stage ivb uterine sarcoma